Lipid conjugation of TLR7 agonist Resiquimod ensures co-delivery with the liposomal Cationic Adjuvant Formulation 01 (CAF01) but does not enhance immunopotentiation compared to non-conjugated Resiquimod+CAF01 - Concepedia

Concepedia

Publication | Closed Access

Lipid conjugation of TLR7 agonist Resiquimod ensures co-delivery with the liposomal Cationic Adjuvant Formulation 01 (CAF01) but does not enhance immunopotentiation compared to non-conjugated Resiquimod+CAF01

24

Citations

55

References

2018

Year

Alexander Wilkinson, Eric Lattmann, Carla B. Roces, Gabriel Kristian Pedersen, Dennis Christensen, Yvonne Perrie

Journal of Controlled Release

InflammationNon-conjugated Resiquimod+caf01ImmunologyLipid ConjugationTherapeutic VaccineAutoimmunityImmunomodulationImmunotherapeuticsMedicineSynthetic ImmunologyTlr7 Agonist Resiquimod

References

	Year	Citations

Page 1